The Bellvitge Institute for Biomedical Research (IDIBELL) is looking for ambitious and highly motivated scientists with an outstanding track record of scientific accomplishments to apply for independent tenure-track Group Leader research positions in the Regenerative Medicine Program. The deadline for applications is December 31st, 2023.
Successful candidates will benefit from:
A vibrant, international, and collaborative environmentA flexible start-up package to set up the lab, the initial team, and to cover lab expensesAccess to state-of-the-art research facilitiesTraining in collaboration with other institutionsTailored support in raising competitive fundsA creative and collaborative environment to nurture excellence Bellvitge Biomedical Research Institute (IDIBELL) is one of the most dynamic health research institutes in Spain with more than 1,200 researchers in the fields of basic, translational, and clinical research who strive to attain significant improvements in human health. The institute was established in 2004 in L'Hospitalet de Llobregat, southern Barcelona metropolitan area. IDIBELL manages the research activities of Bellvitge University Hospital, the Catalan Institute of Oncology (Hospitalet), the University of Barcelona (Bellvitge Campus), and its own researchers. Research is structured into four thematic areas (cancer, neurosciences, translational medicine, and regenerative medicine). IDIBELL's vision is turning Bellvitge Health Area into a health hub of excellence, thanks to its combination of comprehensive medical care, research experience, and unique economic environment. IDIBELL is an accredited Health Research Institute by the Carlos III Institute of Health.
The Regenerative Medicine Program of IDIBELL integrates fundamental and translational research on the use of cells and tissues to treat degenerative diseases. The Program is currently composed of 8 independent research groups whose activities span broad areas of science, including stem cell biology, developmental biology, regeneration and aging, development of advanced therapies, and molecular mechanisms of disease. Researchers within the Regenerative Medicine Program of IDIBELL employ experimental systems that range from zebrafish and mice to human pluripotent stem cells and organoids. The Program also hosts the Barcelona Stem Cell Bank, a node of the Carlos III Institute of Health's Spanish Cell Bank, which generates, registers, and banks human iPS cell lines.
The Regenerative Medicine Program of IDIBELL is a key part of the Program for the Clinical Translation of Regenerative Medicine in Catalonia (P-CMR[C]), a transversal action in the Catalan environment that brings together the relevant stakeholders for advancing the clinical translation of strategies of regenerative medicine based on the use of pluripotent stem cells.
Selection procedure Interested candidates should submit an updated resume, a motivation letter, a brief outline of future research plans (2-3 pages max), and contact details of three referees through IDIBELL's Job Offers Tool by December 31st, 2024. Informal inquiries are welcome and should be addressed to the Coordinator of the Regenerative Medicine Program, Prof. Angel Raya at ******.
Candidates pre-selected by an international scientific committee will be invited for an onsite interview by mid-February 2025 at IDIBELL. The panel will consist of the internal selection committee and members of the international scientific advisory board.
An official offer letter will be issued in writing to the selected candidates.
Employment conditions The successful candidate will lead an independent research group with no teaching obligations and will be appointed for an initial 4-year tenure-track period, starting during 2026.
We offer a flexible start-up package that covers salaries and consumables for up to three positions.
Internal resources Group leaders at IDIBELL's Regenerative Medicine Program benefit from a highly collaborative, approachable, and international English-speaking environment.
We provide fully equipped laboratory space for up to 6-8 people, priority access to onsite facilities, and access to additional special equipment if required.
Besides the laboratories and stem cell culture facilities, IDIBELL hosts a complete Core Facility Unit, offering support in Molecular Interactions, Spatial Genomics & Transcriptomics, Flow Cytometry, Bioimaging, and Histology Platforms, and services in Animal Facility (including aquatic animals), Biobank, Bioinformatics, Biostatistics, and Clinical Trials.
IDIBELL policy of equal opportunities IDIBELL is committed to the principles of the Code of Conduct for the Recruitment of Researchers of the European Commission and the implementation of open, transparent, and merit-based recruitment (OTMR).
Data protection notice In compliance with the obligations established in the General Regulation of Data Protection (RGPD), it is reported that the Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) will process your personal data to apply for the position, maintain communication concerning the status of the candidature, and verify the information provided. You can find more information in our Privacy Policy at https://idibell.cat/en/privacy-policy-2/.
#J-18808-Ljbffr